罗替戈汀
医学
透皮贴片
皮肤病科
皮肤贴
皮肤屏障
麻醉
药理学
疾病
内科学
帕金森病
透皮
作者
Yuki Yasutaka,Shinsuke Fujioka,Hirotomo Shibaguchi,Fumiaki Kiyomi,Koyomi Hara,Kentaro Ogata,Yoshio Tsuboi,Hidetoshi Kamimura
出处
期刊:PubMed
[National Institutes of Health]
日期:2017-09-01
卷期号:69 (9): 1047-1053
被引量:3
标识
DOI:10.11477/mf.1416200865
摘要
Since the effect of a percutaneous absorption-type dopamine agonist (DA) preparation, rotigotine patch, stably persists by once-a-day application, this dosage form is appropriate for Parkinson's disease patients showing levodopa induced wearing off phenomenon. On the other hand, skin disorders, mainly application site reaction, are characteristic problems associated with use of the patch. In this study, to clarify the influence of a topical agent used to prevent or treat rotigotine patch-induced skin disorder on continuation of the patch application, patients who started rotigotine patch application at our hospital were retrospectively surveyed. The one-year continuation rate of rotigotine patch application was 37.3% (53 of 142 cases). It was insufficient to prevent skin disorders, only by the pre-treatment of a moisturizing agent alone. Regarding the effective rate of topical agents used to treat skin disorders, that of very strong-class steroids was 89.5%, being significantly higher than those of weak steroids, moisturizing agents, and antihistamines. It was suggested that for countermeasures against rotigotine patch-induced skin disorders, treatment with very strong-class steroids for external use early after development of skin disorders is more effective than preventive treatment with topical agents regardless of the type. (Received March 30, 2017; Accepted May 16, 2017; Published September 1, 2017).
科研通智能强力驱动
Strongly Powered by AbleSci AI